reviewed april 2026|next review october 2026|88 physicians psi has verified|6 published studies
Beta-Glucan Peptide
Beta-glucan peptides are protein-bound polysaccharides isolated from medicinal mushrooms (primarily Coriolus versicolor PSP/PSK) that activate innate immunity through Dectin-1 and TLR2/6 receptors, with regulatory approval as cancer adjunct therapies in Japan and China.
Evidence landscape: 6 published studies
4,700+ published studies on beta-glucan immunology. Clinical studies concentrated in Asian cancer immunotherapy research.
- 6 Animal
PSK (Krestin) is approved in Japan and PSP is approved in China as cancer immunotherapy adjuncts. These approvals are based on clinical trial data in those jurisdictions.
Activates innate immune cells (macrophages, NK cells, dendritic cells) through pattern recognition receptors including Dectin-1, complement receptor 3, and TLR2.
Not FDA-approved. Available as dietary supplements. Standardization and potency vary across products.
PSI Assessment
Beta-glucan peptides from medicinal mushrooms are among the few immune supplements with genuine regulatory approval in any jurisdiction. PSK (Krestin) is approved in Japan and PSP is approved in China as cancer immunotherapy adjuncts, based on clinical studies in cancer patients. The immune activation mechanism is well-characterized: beta-glucans bind Dectin-1 and other pattern recognition receptors on innate immune cells, enhancing macrophage activity and NK cell cytotoxicity. In the US, these compounds are available as dietary supplements with no FDA approval. The key uncertainty is whether the clinical evidence from Asian regulatory frameworks translates to the standardization and quality expectations of Western clinical practice.
Approved as cancer immunotherapy adjuncts in Japan and China. Immune activation through characterized receptors (Dectin-1, CR3). Not FDA-approved.
Beta-glucan peptides activate innate immunity through Dectin-1, complement receptor 3 (CR3), and TLR2 on macrophages and dendritic cells. This triggers phagocytosis, cytokine production (TNF-alpha, IL-1, IL-6, IL-12), NK cell activation, and Th1 immune responses. The peptide portion of polysaccharide-peptide conjugates may add specificity to the immune activation pattern. PSK/PSP are the best-studied variants, with clinical use primarily in Asia as adjuncts to standard cancer therapy (chemotherapy and radiation), not as standalone treatments.
What the evidence supports
Innate immune activation through characterized receptors (Dectin-1, CR3, TLR2). Macrophage activation and NK cell cytotoxicity enhancement documented in multiple studies. PSK/PSP from Coriolus versicolor are approved as cancer adjunct therapies in Japan and China with clinical trial support.
What is not yet established
FDA approval for any indication. Whether immune enhancement produces meaningful survival benefits as a standalone therapy. Standardization of potency across different mushroom-derived preparations. Whether peptide conjugation provides advantages over purified beta-glucan alone.
Research Evidence
The findings below cover the immune activation mechanism, clinical evidence from Asian regulatory frameworks, and the standardization challenge.
Evidence by condition
Evidence dimensions across beta-glucan peptide applications. Immune modulation and cancer adjunct therapy have the most clinical backing.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Immune Modulation | ||||
| Cancer Adjunct Therapy |
Beta-glucan peptides activate innate immunity through pattern recognition receptors including Dectin-1, complement receptor 3, and TLR2/6. This triggers macrophage activation, cytokine production, NK cell cytotoxicity, and dendritic cell maturation.
The receptor-level mechanism is well-characterized. Multiple independent research groups confirm the immune activation pathway.
PSK (Krestin) from Coriolus versicolor is approved in Japan and PSP is approved in China as cancer immunotherapy adjuncts. Clinical studies show immune enhancement in cancer patients receiving chemotherapy.
The regulatory approvals in Japan and China are based on clinical trial data. However, these approvals occurred under different regulatory standards than FDA requirements.
NK cell activity enhancement and Th1 immune response promotion are documented in clinical studies of cancer patients. Beta-glucan peptides are used as adjuncts to standard oncology treatment, not as standalone cancer therapies.
The adjunct use distinction is important. The evidence supports immune enhancement alongside conventional treatment, not replacement of it.
0 Human|6 Animal|0 Reviews
View all 6 indexed studiesHow Beta-Glucan Peptide Works
Beta-glucan peptides are protein-bound polysaccharides from medicinal mushrooms that activate innate immune cells through Dectin-1, complement receptor 3, and TLR2/6, enhancing macrophage function, NK cell cytotoxicity, and dendritic cell maturation.
Activates immune first responders: macrophages, natural killer cells, and dendritic cells. Acts like a training signal that keeps immune defenses alert without causing inflammation.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Beta-glucan peptides bind Dectin-1, complement receptor 3 (CR3), and TLR2 on innate immune cells. Dectin-1 engagement activates Syk kinase signaling, promoting phagocytosis and NF-kB-mediated cytokine production (TNF-alpha, IL-1, IL-6, IL-12). CR3 engagement primes neutrophils for complement-mediated cytotoxicity. The peptide conjugate portion may enhance receptor binding specificity and provide additional immunomodulatory signaling. PSK and PSP differ in their polysaccharide branching patterns and peptide composition, which may account for different immune activation profiles.
What is Beta-Glucan Peptide being studied for?
Researchers are studying Beta-Glucan Peptide across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Beta-Glucan Peptide overall. This means a compound can have human studies for one condition but only animal data for another.
Immune Modulation
·Animal StudiesActivates innate immune pathways through characterized receptors. Enhances macrophage and NK cell activity. Used as immune support supplements.
Limitations: Potency and standardization vary across products and mushroom species. Whether supplement-grade preparations achieve the same immune activation as research-grade extracts is uncertain.
Cancer Adjunct Therapy
·Human TrialsPSK/PSP are approved as cancer immunotherapy adjuncts in Japan and China. Clinical studies show immune enhancement in cancer patients alongside chemotherapy and radiation.
Limitations: Not FDA-approved. Evidence base is geographically concentrated in Asia. Whether immune enhancement translates to meaningful survival benefits as adjunct therapy requires further validation.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Available as dietary supplements in the US. Approved as cancer adjuncts in Japan (PSK/Krestin) and China (PSP).
Availability: Widely available over the counter as dietary supplements. Product quality and standardization vary significantly.
Class context: Generally well tolerated with rare GI discomfort. Use cautiously in autoimmune conditions where immune stimulation may be counterproductive.
Generally well tolerated and widely available. The most important safety consideration is for individuals with autoimmune conditions, where immune stimulation may be counterproductive. Product quality varies across supplement brands.
Questions and Comparisons
Questions the evidence raises for a Beta-Glucan Peptide discussion.
Comparison and Related Research
Beta-glucan peptides are most often compared with other immunomodulatory peptides and supplements.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Comprehensive review of the immunological effects of PSP (polysaccharopeptide) from Coriolus versicolor, documenting immune cell activation, cytokine modulation, and antitumor properties in laboratory and clinical studies.Ng TB, 1998 in Gen Pharmacol. View on PubMed
- 2.Clinical study showing that PSP supplementation slowed disease progression in patients with advanced non-small cell lung cancer receiving standard treatment, supporting the cancer adjunct therapy application.Tsang KW et al., 2003 in QJM. View on PubMed
- 3.Demonstrated measurable immune cell enhancement in cancer patients receiving Coriolus versicolor polysaccharide-peptide supplements, confirming that the immune activation observed in laboratory studies translates to human immune function.Chan SL et al., 2009 in Mol Nutr Food Res. View on PubMed
- 4.Characterized the Dectin-1 and complement receptor 3 (CR3) signaling pathways through which beta-glucans activate innate immune cells, establishing the molecular mechanism behind beta-glucan peptide immunomodulation.Brown GD & Gordon S, 2003 in Nature. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.